Who Paid My Doc
Vikas Satyananda
Surgical Oncology Columbia, MO Medical Doctor
NPI 1467893727 CMS profile 2791277
One Hospital Dr, Columbia, MO 65212
General payments
$3,186
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Vikas Satyananda of Columbia, MO is reported in the CMS Open Payments database as having received $3,186 across 16 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 64th percentile of Surgical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $3,013 | 13 | |
| 2024 | General | $3 | 1 | |
| 2021 | General | $150 | 1 | |
| 2019 | General | $21 | 1 |
Beside peers
- Vikas Satyananda
- Surgical Oncology median
- Middle half of Surgical Oncology
- National median
In program year 2025, general payments to Vikas Satyananda were reported at $3,013. Among 1,137 Surgical Oncology profiles paid that year, the median was $288 and the middle half received between $118 and $1,346.
Show as a table
| Year | Vikas Satyananda | Surgical Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $21 | $236 | $86–$1,064 | $163 |
| 2020 | $0 | $130 | $47–$648 | $114 |
| 2021 | $150 | $160 | $53–$943 | $132 |
| 2022 | $0 | $199 | $76–$782 | $149 |
| 2023 | $0 | $246 | $95–$854 | $160 |
| 2024 | $3 | $271 | $106–$1,123 | $164 |
| 2025 | $3,013 | $288 | $118–$1,346 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 32 billing codesPaid by Medicare
$13,836
Medicare patients
61
Services billed
124
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 43% | |
| Diabetes | 31% | |
| Ischemic heart disease | 30% | |
| Cancer | 30% | |
| Atrial fibrillation | 21% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
16 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Surgical Oncology in Missouri
Peter Dipasco
Surgical Oncology · Saint Louis, MO
Trang Nguyen
Surgical Oncology · Saint Louis, MO
Rebecca Aft
Surgical Oncology · Saint Louis, MO
Ana Belzarena Genovese
Surgical Oncology · Columbia, MO
Julie Margenthaler
Surgical Oncology · Saint Louis, MO
Charles Woodall
Surgical Oncology · Springfield, MO
Related records
Surgical Oncology in Missouri
Practitioners in the same specialty and state, ranked by reported value.
All Surgical Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Missouri
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.